Metastatic Breast Cancer - Pipeline Review, H1 2013

Every year, different research firms will do a pipeline review.   I remember at one time, there were about 400 in the pipeline.  Many of these proposed MBC drugs were developed originally for other cancer/conditions, their effect on MBC is probably a good side-effect, but one could hardly expect miraculous cure from it.    Others were pre-clinical, and it's not clear whether they will ever make it to early clinical trials for MBC.   

I expect if I track the number of drugs, I may be able to tell if NIH sequester funding cut is going to cause a drop maybe 5 year from now.   It will be hard for the graduate students being sent away for funding cut, and then come back and continue their work.   Or maybe new graduate students be hired, research labs won't open at all.